Fairtility wins Women’s Health Innovation Award at MedTech Breakthrough Awards

Fairtility, the transparent AI innovator powering IVF for improved outcomes, has announced that its CHLOE tool has won the Women’s Health Innovation Award at the annual MedTech Breakthrough Awards.

Achieving CE MDR approval in June 2022, CHLOE is the first and only transparent AI-based decision support tool providing clinicians and prospective parents with visibility into clinical and laboratory data to help improve IVF outcomes.

Fairtility leverages advanced data collection capabilities to train its algorithms on large, diverse data sets.

Its proprietary AI-powered embryo quality assessment assistant, CHLOE EQ, processes millions of data points undetectable to the human eye, offering quantitative and qualitative data to IVF professionals to create a fully digitised workflow in the lab for embryo selection, alongside clearly explainable embryo analysis results based on quantifiable biological parameters.

This results in increased transparency, streamlined workflows and reduced administrative steps in the IVF process.

The clinical accuracy of CHLOE’s automated annotations supports embryologists in making knowledgeable decisions based on detailed embryo quality data.

The tool provides insights in biological terms, to help IVF professionals make informed decisions and foster open, informed conversations on treatment options and next steps alongside patients.

“Infertility affects one in six people – both male and female – globally. Despite advancements in fertility medicine, IVF success rates still stand at ~30 per cent per cycle,” explained Eran Eshed, CEO and co-founder of Fairtility.

“This field is ripe for transformation, and CHLOE EQ’s breakthrough technology is making IVF into a significantly more transparent process.

“As more people seek out fertility treatment, CHLOE intends to become a key tool in making IVF a more streamlined, transparent, effective and accessible process for patients desiring to be parents.”

MedTech Breakthrough Awards,  conducted by the independent market intelligence organisation MedTech Breakthrough, aims to honour excellence and recognise the innovation, hard work and success across a range of health and medical technology categories, including telehealth, clinical administration, patient engagement, electronic health records (EHR), virtual care, medical devices, medical data and many more.

This year’s programme attracted more than 4,000 nominations from over 17 different countries.

James Johnson, managing director at MedTech Breakthrough, said: “The need for assistive reproductive solutions is increasing as the gap between IVF supply and demand keeps expanding.

“The limited number of reproductive endocrinologists and embryologists cannot meet the demand of prospective parents.

“Fairtility’s breakthrough CHLOE solution addresses this challenge, delivering reproducible results backed by evidence-based research, cultivating reliability, transparency, and trust for IVF professionals using CHLOE EQ.

“This could enable a reduction in time to pregnancy for prospective parents yearning to start their families. Congratulations on being our pick for the Women’s Health Innovation Award!”